(Press-News.org) The use of cell therapy to treat COVID-19 patients can reduce the risk of death from the disease by 60%, according to a systematic review and meta-analysis conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States.
Their findings are reported in an article published in the journal Frontiers in Immunology.
The review covers 195 clinical trials of advanced cell therapies targeting COVID-19 that were conducted in 30 countries between January 2020 and December 2021, as well as 26 trials with outcomes published by July 2022.
Cell therapy has come into increasingly frequent use in recent years to treat several diseases, especially cancer. It consists basically of introducing healthy cells into the patient’s organism in order to restore or alter certain sets of cells, carry a therapy through the body, or modulate the function of diseased cells.
The technique uses stem cells and derivatives from the patient (autologous) or from a donor (allogenic). The cells are cultured or modified in the laboratory before being administered. According to the article, the cell types most frequently used in clinical trials relating to treatment of COVID-19 in the period were multipotent mesenchymal stem (stromal) cells from connective tissue, used in 72% of the studies reviewed; natural killer cells from lymphoblasts, used in 9%; and mononuclear cells from blood, used in 6%.
“Cell therapy has advanced significantly in recent years and has been used to treat cancer and auto-immune, heart and infectious diseases. During the pandemic, it was used to treat COVID-19 in several clinical trials. Our study is the first to review all the information on these experiences scattered around the world and to verify by means of a meta-analysis [a statistical method of aggregating data from many independent studies] how cell therapy functions when used to treat COVID-19 and related complications,” said Otávio Cabral-Marques, a professor at USP’s Medical School and coordinator of the study.
Stem cell therapy and models involving organoids derived from stem cells drew a great deal of attention as novel methods for treating and studying COVID-19 during the pandemic, he noted, given the significant immune regulatory power and tissue repair functions of stem cells, especially the mesenchymal variety. In the case of the lungs, for example, clinical trials have shown to a greater or lesser extent that advanced cell therapy can limit the severity of the inflammatory response in COVID-19 patients, reduce pulmonary damage, improve lung function and help combat fibrosis.
Despite the attention paid to cell therapy, the real protection assured by vaccination should be stressed, according to Cabral-Marques. “Although all these studies have shown that advanced cell therapy could become established soon as an important adjunct treatment for these patients, prevention of the disease by vaccination remains the best protection,” he said.
Data standardization
The clinical trials involving advanced cell therapy for COVID-19 analyzed by the authors of the review article were conducted in 30 countries, mainly the United States, China, Iran and Spain. They were highly heterogeneous, however, with widely varying numbers of participants, designs and methodologies, so for meta-analysis purposes the researchers created a specially curated COVID-19 trials database at CellTrials.org with several quality refinements, such as inclusion of trials from all national registries, exclusion of false positives on keywords, and exclusion of double counting of the same trials.
The authors also note differences in terms of the phases of trials. In many countries, especially in Europe, strict regulation limits the number of human cell therapy products with established safety profiles that can be trialed, and 56% of the trials did not reach phase 2, which typically focuses on determining safety, efficacy and dose-response in a few hundred volunteers with the disease. Another limitation was that 31% of the trials analyzed did not have a control group.
“To arrive at such a large reduction in the risk of death, we had to take into account the findings and characteristics of the different studies, as well as making a certain number of corrections and estimates,” said Igor Salerno Filgueiras, a PhD candidate and co-author of the article.
“There are techniques to standardize the data, eliminate biases and produce an impartial result, enabling analysts to reach conclusions that often go unnoticed in a specific study but add up to relevant scientific evidence when they are reinforced by other data,” said Dennyson Leandro M. Fonseca, another co-author and the recipient of a PhD scholarship from FAPESP.
Fabrication and clinical delivery methods in studies involving mesenchymal stem cells were “remarkably heterogeneous”, according to the article. “The results highlight the important role these cells can play in adjuvant therapies for COVID-19 and the associated complications. However, they also point to a need for better control of key parameters relating to the way the cell therapy products are made if we are to assure comparability between studies,” Cabral-Marques said.
About São Paulo Research Foundation (FAPESP)
The São Paulo Research Foundation (FAPESP) is a public institution with the mission of supporting scientific research in all fields of knowledge by awarding scholarships, fellowships and grants to investigators linked with higher education and research institutions in the State of São Paulo, Brazil. FAPESP is aware that the very best research can only be done by working with the best researchers internationally. Therefore, it has established partnerships with funding agencies, higher education, private companies, and research organizations in other countries known for the quality of their research and has been encouraging scientists funded by its grants to further develop their international collaboration. You can learn more about FAPESP at www.fapesp.br/en and visit FAPESP news agency at www.agencia.fapesp.br/en to keep updated with the latest scientific breakthroughs FAPESP helps achieve through its many programs, awards and research centers. You may also subscribe to FAPESP news agency at http://agencia.fapesp.br/subscribe.
END
Cell therapy can reduce risk of death from COVID-19 by 60%, study shows
Brazilian researchers and collaborators in Germany and the US compiled data from 195 clinical trials conducted in 30 countries between January 2020 and December 2021.
2023-09-18
ELSE PRESS RELEASES FROM THIS DATE:
The pace of climate-driven extinction is accelerating, a UArizona-led study shows
2023-09-18
Climate change is causing extinctions at an increasing rate, a new study by the University of Arizona researchers shows. They surveyed populations of the Yarrow's spiny lizard in 18 mountain ranges in southeastern Arizona and analyzed the rate of climate-related extinction over time.
"The magnitude of extinction we found over the past seven years was similar to that seen in other studies that spanned almost 70 years," said John J. Wiens, a professor in the Department of Ecology and Evolutionary Biology at UArizona, ...
Nuclear medicine treatment cures lethal form of ovarian cancer in preclinical setting
2023-09-18
Reston, VA—A new 225Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects. Targeting the HER2 protein, which is commonly expressed in ovarian cancer, the therapy (anti-HER2 225Ac-PRIT) is a potential treatment for the otherwise incurable disease. This research was published in the September issue of The Journal of Nuclear Medicine.
Epithelial ovarian cancer is the most lethal ovarian cancer and frequently presents as advanced-stage disease, ...
Gene links exercise endurance, cold tolerance, and cellular maintenance in flies
2023-09-18
EMBARGOED FOR RELEASE UNTIL September 18, 2023 at 3:00 PM U.S. Eastern time
As the days get shorter and chillier in the northern hemisphere, those who choose to work out in the mornings might find it harder to get up and running. A new study in PNAS identifies a protein that, when missing, makes exercising in the cold that much harder—that is, at least in fruit flies.
A team from University of Michigan Medical School and Wayne State University School of Medicine discovered the protein in flies, which they named Iditarod after the famous long distance dog sled across Alaska, while studying metabolism and the effect of stress on the body.
They were particularly ...
Eureka baby! Groundbreaking study uncovers origin of ‘conscious awareness’
2023-09-18
Living things act with purpose. But where does purpose come from? How do humans make sense of their relation to the world and realize their ability to effect change? These fundamental questions of agency – acting with purpose – have perplexed some of the greatest minds in history including Sir Isaac Newton, Charles Darwin, Erwin Schrödinger and Niels Bohr.
A Florida Atlantic University study reveals groundbreaking insight into the origins of agency using an unusual and largely untapped source – human babies. Since goal-directed action appears in the first months ...
Study finds human-driven mass extinction is eliminating entire branches of the tree of life
2023-09-18
The passenger pigeon. The Tasmanian tiger. The Baiji, or Yangtze river dolphin. These rank among the best-known recent victims of what many scientists have declared the sixth mass extinction, as human actions are wiping out vertebrate animal species hundreds of times faster than they would otherwise disappear.
Yet, a recent analysis from Stanford University and the National Autonomous University of Mexico, published this week in the Proceedings of the National Academy of Sciences, shows the crisis may run even deeper. Each of the three species above was also the ...
An implantable device could enable injection-free control of diabetes
2023-09-18
CAMBRIDGE, MA -- One promising approach to treating Type 1 diabetes is implanting pancreatic islet cells that can produce insulin when needed, which can free patients from giving themselves frequent insulin injections. However, one major obstacle to this approach is that once the cells are implanted, they eventually run out of oxygen and stop producing insulin.
To overcome that hurdle, MIT engineers have designed a new implantable device that not only carries hundreds of thousands of insulin-producing islet cells, but also has its own on-board oxygen factory, which generates oxygen by splitting water vapor found in the body.
The researchers showed that when ...
Buried ancient Roman glass formed substance with modern applications
2023-09-18
Some 2,000 years ago in ancient Rome, glass vessels carrying wine or water, or perhaps an exotic perfumes, tumble from a table in a marketplace, and shatter to pieces on the street. As centuries passed, the fragments were covered by layers of dust and soil and exposed to a continuous cycle of changes in temperature, moisture, and surrounding minerals.
Now these tiny pieces of glass are being uncovered from construction sites and archaeological digs and reveal themselves to be something extraordinary. On their surface is a mosaic of iridescent colors of blue, green and orange, with some displaying shimmering gold-colored ...
Genomes of enigmatic tusk shells provide new insights into early Molluscan evolution
2023-09-18
Accurate phylogenetic trees are fundamental to evolutionary and comparative biology, but the almost simultaneous emergence of major animal phyla and diverse body plans during the Cambrian Explosion poses major challenges to reconstructing deep metazoan phylogenetic relationships.
This is particularly true for the second largest phylum, Mollusca, whose major lineages originated in the Cambrian period. The diverse fossil record, extreme morphological disparity among the eight living classes, and dramatic conflict among phylogenetic hypotheses due to diverse paleontological, ...
Remote work can slash your carbon footprint — if done right
2023-09-18
ITHACA, N.Y. – Remote workers can have a 54% lower carbon footprint compared with onsite workers, according to a new study by Cornell University and Microsoft, with lifestyle choices and work arrangements playing an essential role in determining the environmental benefits of remote and hybrid work.
The study, published in the Proceedings of the National Academy of Sciences, also finds that hybrid workers who work from home two to four days per week can reduce their carbon footprint by 11% to 29%, but working from home one day per week ...
Preschoolers from low-income families may have worse health and benefit less from health promotion interventions than children with higher socioeconomic status
2023-09-18
Low socioeconomic status can negatively impact children’s health in preschool, along with their ability to follow specialized health education intervention programs, Mount Sinai researchers found in an international study focused on health promotion in schools, including those in the Harlem section of New York City. The results, published September 18 in the Journal of American College of Cardiology, stress the importance of introducing a specialized health curriculum in classrooms starting in preschool.
“This study shows that socioeconomic factors, including lower household income and education level, can negatively impact children’s health starting ...
LAST 30 PRESS RELEASES:
Hearing angry or happy human voices is linked to changes in dogs’ balance
Microplastics are found in a third of surveyed fish off the coasts of remote Pacific Islands
De-stigmatizing self-reported data in health care research
US individuals traveling from strongly blue or red US counties may favor everyday travel to like-minded destinations
Study reveals how superionic state enables long-term water storage in Earth's interior
AI machine learning can optimize patient risk assessments
Efficacy of immunosuppressive regimens for survival of stem cell-derived grafts
Glowing bacterial sensors detect gut illness in mice before symptoms emerge
GLP-1 RAs and prior major adverse limb events in patients with diabetes
Life-course psychosocial stress and risk of dementia and stroke in middle-aged and older adults
Cells have a built-in capacity limit for copying DNA, and it could impact cancer treatment
Study finds longer hospital stays and higher readmissions for young adults with complex childhood conditions
Study maps how varied genetic forms of autism lead to common features
New chip-sized, energy-efficient optical amplifier can intensify light 100 times
New light-based platform sets the stage for future quantum supercomputers
Pesticides significantly affect soil life and biodiversity
Corals sleep like us, but their symbiosis does not rest
Huayuan biota decodes Earth’s first Phanerozoic mass extinction
Beyond Polymers: New state-of-the-art 3D micro and nanofabrication technique overcomes material limitations
New platform could develop vaccines faster than ever before
TF-rs1049296 C>T variant modifies the association between hepatic iron stores and liver fibrosis in metabolic dysfunction-associated steatotic liver disease
ASH publishes clinical practice guidelines on diagnosis of light chain amyloidosis
SLAS receives grant from Alfred P. Sloan Foundation to develop lab automation educational guidelines
Serum interleukin-8 for differentiating invasive pulmonary aspergillosis from bacterial pneumonia in patients with HBV-associated acute-on-chronic liver failure
CIIS and the Kinsey Institute present "Desire on the Couch," an exhibition examining psychology and sexuality
MRI scan breakthrough could spare thousands of heart patients from risky invasive tests
Kraft Center at Mass General Brigham launches 2nd Annual Kraft Prize for Excellence and Innovation in Community Health
New tool shows how to enter and change pneumocystis fungi
Applications of artificial intelligence and smart devices in metabolic dysfunction-associated steatotic liver disease
New clinical trial demonstrates that eating beef each day does not affect risk factors for type 2 diabetes
[Press-News.org] Cell therapy can reduce risk of death from COVID-19 by 60%, study showsBrazilian researchers and collaborators in Germany and the US compiled data from 195 clinical trials conducted in 30 countries between January 2020 and December 2021.